PTYLTD
    • Insights
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Insights

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic
  • Insights From Technical Analysis

Insights From Technical Analysis

4DMedical (ASX: 4DX)

4DMedical (ASX: 4DX): Funding Risk Behind the High-Growth MedTech Hype?

Apr 15, 2026
Proactive Equities Team

4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.

Our high-conviction gold opportunity for 2026

Our high-conviction gold opportunity for 2026

Mar 24, 2026
Proactive Equities Team

This ASX gold producer is undervalued due to limited production history, but strong early margins suggest significant profit potential and a possible near-term re-rating. It operates a low-risk open-pit mine with long reserves, resources, and added silver by-product exposure.

New Murchison Gold (ASX: NMG)

New Murchison Gold (ASX: NMG): Pay for the Current Gold, Get the Exploration Potential for Free

Mar 14, 2026
Proactive Equities Team

New Murchison Gold Limited is a small Australian gold producer operating the Crown Prince mine in Western Australia. The company recently transitioned from exploration to production and is generating strong cash flow from high-grade ore sold to Westgold Resources Limited. Exploration at nearby targets and potential underground mining could extend the project’s life and add future growth potential.

Electro Optic Systems (ASX: EOS)

Electro Optic Systems (ASX: EOS): Pricing the Counter-Drone and Laser Defence Opportunity

Mar 14, 2026
Proactive Equities Team

Electro Optic Systems develops remote weapon systems, counter-drone platforms and laser defence technologies for military customers. Despite strong order-book growth and rising defence demand, the company still generates operating losses and negative cash flow. Its valuation is largely based on future growth in counter-drone and directed-energy defence systems.

RACURA Oncology Ltd (ASX: RAC)

Racura Oncology (ASX: RAC): Could RC220 Turn This Small Biotech into a Billion-Dollar Cancer Stock?

Mar 13, 2026
Proactive Equities Team

Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.

Telix Pharmaceutical (ASX: TLX)

Has Telix Pharmaceutical's (ASX: TLX) share price reached the bottom?

Mar 13, 2026
Proactive Equities Team

Telix Pharmaceuticals is a radiopharmaceutical company focused on cancer imaging and therapies, with strong revenue growth driven by products like Illuccix and Gozellix. While recent gains suggest the stock may be stabilising, future performance will depend on continued commercial growth and pipeline progress.

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics
Videos

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...484950...56
Page 49 of 56